Final trial results continue to show benefit from remdesivir for COVID-19

Final results from a randomized clinical trial continued to show that remdesivir shortens recovery time in hospitalized patients with COVID-19, although researchers said antiviral treatment alone is probably not sufficient for all patients. The final report from the Adaptive COVID-19 Treatment Trial (ACCT-1) was published today in The New England Journal of Medicine. Preliminary results from the

Read the full article here

Related Articles